オクトレオチド市場：市場規模、予測、市場洞察-2032年

オクトレオチドは、合成ソマトスタチン類似体であり、血管作動性腸管ペプチド（VIP）などの多くのホルモンの分泌低下、腸管通過時間の延長、水分および電解質の分泌低下と吸収増加など、いくつかのメカニズムを介して作用します。米国食品医薬品局（FDA）により、VIP分泌腫瘍に関連した下痢およびカルチノイド症候群による症状の治療薬として承認されています。オクトレオチドはフルオロピリミジン、イリノテカン、および5-FUベースの化学放射線療法によるCIDの患者に有益です。5-FU治療患者41人を対象とした1件のランダム化試験で、オクトレオチドは標準用量のロペラミドよりも有効であることが示されましたが（3日目までの下痢の消失率は90％対15％）、オクトレオチドはコストが高いため、一般に、ロペラミドの増量にもかかわらず48時間後に不応となった患者に対する第2選択治療として留保されています。重度の下痢、吐き気、嘔吐、食欲不振、腹部けいれんなどの消化器症候群を発症した患者には、点滴とオクトレオチドの前投与による積極的な管理が必要です。

今後数年間で、化学療法誘発性下痢（CID）の市場シナリオは、世界中の広範な調査と医療支出の増加により変化します。各社は、病状を治療/改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、オクトレオチドの優位性に影響を与える可能性のある機会を模索しています。CIDに対する他の新興製品がオクトレオチドに厳しい市場競争を与えることが予想され、近い将来、後発の新興治療薬の発売が市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国における化学療法誘発性下痢（CID）治療薬のオクトレオチド市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 CIDにおけるオクトレオチドの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 オクトレオチド市場評価

• CIDにおけるオクトレオチドの市場見通し
• 主要7ヶ国分析
  • 主要7ヶ国のCIDにおけるオクトレオチドの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Octreotide, Clinical Trial Description, 2023
• Table 2: Octreotide, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: Octreotide Market Size in the 7MM, in USD million (2019-2032)
• Table 6: Octreotide Market Size in the US, in USD million (2019-2032)
• Table 7: Octreotide Market Size in Germany, in USD million (2019-2032)
• Table 8: Octreotide Market Size in France, in USD million (2019-2032)
• Table 9: Octreotide Market Size in Italy, in USD million (2019-2032)
• Table 10: Octreotide Market Size in Spain, in USD million (2019-2032)
• Table 11: Octreotide Market Size in the UK, in USD million (2019-2032)
• Table 12: Octreotide Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Octreotide Market Size in the 7MM, USD million (2019-2032)
• Figure 2: Octreotide Market Size in the United States, USD million (2019-2032)
• Figure 3: Octreotide Market Size in Germany, USD million (2019-2032)
• Figure 4: Octreotide Market Size in France, USD million (2019-2032)
• Figure 5: Octreotide Market Size in Italy, USD million (2019-2032)
• Figure 6: Octreotide Market Size in Spain, USD million (2019-2032)
• Figure 7: Octreotide Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Octreotide Market Size in Japan, USD million (2019-2032)

"Octreotide Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about octreotide for Chemotherapy-induced Diarrhea (CID) in the seven major markets. A detailed picture of the octreotide for CID in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the octreotide for CID. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the octreotide market forecast analysis for CID in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in CID.

Drug Summary:

Octreotide, a synthetic somatostatin analog, acts via several mechanisms: decreased secretion of a number of hormones, such as vasoactive intestinal peptide (VIP); prolongation of intestinal transit time and reduced secretion and increased absorption of fluid and electrolytes. It is approved by the US Food and Drug Administration for the treatment of diarrhea related to VIP-secreting tumors and symptoms due to carcinoid syndrome. Octreotide is beneficial in patients with CID from fluoropyrimidines, irinotecan, and 5-FU-based chemoradiotherapy. Although one randomized trial in 41 5-FU-treated patients showed that octreotide was more effective than standard-dose loperamide (90 versus 15% resolution of diarrhea by day 3), octreotide is generally reserved as a second-line treatment for patients who are refractory after 48 hours, despite a loperamide escalation, because of its high cost. Patients developing a gastrointestinal syndrome including severe diarrhea, nausea, vomiting, anorexia, and abdominal cramping should receive an aggressive management with intravenous fluids and upfront octreotide.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the octreotide description, mechanism of action, dosage and administration, research and development activities in Chemotherapy-induced Diarrhea (CID).
• Elaborated details on octreotide regulatory milestones and other development activities have been provided in this report.
• The report also highlights the octreotide research and development activities in CID across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around octreotide.
• The report contains forecasted sales of octreotide for CID till 2032.
• Comprehensive coverage of the late-stage emerging therapies for CID.
• The report also features the SWOT analysis with analyst views for octreotide in CID.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Octreotide Analytical Perspective by DelveInsight

• In-depth Octreotide Market Assessment

This report provides a detailed market assessment of octreotide for Chemotherapy-induced Diarrhea (CID) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• Octreotide Clinical Assessment

The report provides the clinical trials information of octreotide for CID covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Chemotherapy-induced Diarrhea (CID) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence octreotide dominance.
• Other emerging products for CID are expected to give tough market competition to octreotide and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of octreotide in CID.
• Our in-depth analysis of the forecasted sales data of octreotide from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the octreotide in CID.

Key Questions:

• What is the product type, route of administration and mechanism of action of octreotide?
• What is the clinical trial status of the study related to octreotide in Chemotherapy-induced Diarrhea (CID) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the octreotide development?
• What are the key designations that have been granted to octreotide for CID?
• What is the forecasted market scenario of octreotide for CID?
• What are the forecasted sales of octreotide in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to octreotide for CID?
• Which are the late-stage emerging therapies under development for the treatment of CID?

Table of Contents

1. Report Introduction

2. Octreotide Overview in CID

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Octreotide Market Assessment

• 5.1. Market Outlook of Octreotide in CID
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Octreotide in the 7MM for CID
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Octreotide in the United States for CID
  • 5.3.2. Market Size of Octreotide in Germany for CID
  • 5.3.3. Market Size of Octreotide in France for CID
  • 5.3.4. Market Size of Octreotide in Italy for CID
  • 5.3.5. Market Size of Octreotide in Spain for CID
  • 5.3.6. Market Size of Octreotide in the United Kingdom for CID
  • 5.3.7. Market Size of Octreotide in Japan for CID

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options